Aurinia Pharmaceuticals (AUPH) Non-Current Deffered Revenue (2016 - 2026)

Aurinia Pharmaceuticals has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $12.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue changed 0.3% year-over-year to $12.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.4 million (changed 0.3% YoY), and the FY2025 full-year result was $12.6 million, up 644.44% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $12.4 million, down from $12.6 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $12.6 million in Q4 2025, with the low at $1.7 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $10.6 million across 3 years, with a median of $12.4 million in 2025.
• Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue jumped 644.44% — and 2026, when it dropped 0.3%.
• Aurinia Pharmaceuticals' Non-Current Deffered Revenue stood at $1.7 million in 2024, then jumped by 644.44% to $12.6 million in 2025, then retreated by 1.86% to $12.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $12.4 million (Q1 2026), $12.6 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.